• KOL
    • Hepatocellular Carcinoma
    • Alejandro Forner
    • Alejandro Forner: Influence Statistics

       Alejandro Forner

      Alejandro Forner

      Show email address

      Liver Unit, Barcelona Clinic Liver Cancer (BCLC) Group, Hospital Clinic Barcelona. IDIBAPS, University of Barcelona, Barcelona, Spain | BCLC group, Liver Unit, Hospital Clínic ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Alejandro Forner:Expert Impact

      Concepts for whichAlejandro Fornerhas direct influence:Hepatocellular carcinoma,Milan criteria,Liver transplantation,20 mm,Gadoxetic acid,Hospital admissions,Hepatocellular carcinoma hcc,Liver neoplasms.

      Alejandro Forner:KOL impact

      Concepts related to the work of other authors for whichfor which Alejandro Forner has influence:Hepatocellular carcinoma,Liver transplantation,Hcc patients,Transarterial chemoembolization,Radiofrequency ablation,Milan criteria.

      KOL Resume for Alejandro Forner

      Year
      2022

      Liver Unit, Barcelona Clinic Liver Cancer (BCLC) Group, Hospital Clinic Barcelona. IDIBAPS, University of Barcelona, Barcelona, Spain

      2021

      Barcelona Clínic Liver Cancer Group (BCLC), University of Barcelona, Barcelona, Spain; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain; Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain; Network for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), Barcelona, Spain.

      Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain

      2020

      Liver Unit, ICMDiM, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain

      2019

      Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clínic of Barcelona, Fundació Clínic per a la Recerca Biomédica (FCRB), IDIBAPS, University of Barcelona, Villarroel 170. Escala 11, 4(a) planta, Barcelona 08036, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. Electronic address:

      Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain

      2018

      Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain

      2017

      Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic‐ IDIBAPS, Barcelona, Spain

      2016

      Network for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

      CIBEREHD (Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas) Madrid Spain

      Unidad de Oncología Hepática (Barcelona Clinic Liver Cancer), Servicio de Hepatología, Hospital Clínic, Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, España

      2015

      Barcelona Clinic Liver Cancer (BCLC) group, Liver Unit, Networked Biomedical Research Centre for Hepatic and Digestive Diseases (CIBERehd), Hospital Clinic Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Carrer Villarroel 170, 08036, Barcelona, Spain

      2014

      Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain

      2013

      Unidad de Oncología Hepática, Servicio de Hepatología, Hospital Clínic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, España

      Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd)

      Hospital Clínic Barcelona, IDIBAPS, University of Barcelona Barcelona Clinic Liver Cancer (BCLC) Group Liver Unit Barcelona Spain

      2012

      Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, España

      Liver Unit, Hospital Clínic., Institut d'Investigacions Biomèdiques August Pi‐Sunyer (IDIBAPS), Ciber de Enfermedades Hepáticas y Digestivas(CIBERehd), University of Barcelona, Barcelona, Spain

      2011

      Unidad de Oncología Hepática (BCLC group), CIBERehd, IDIBAPS, Hospital Clínic, Barcelona, España

      Barcelona Clinic Liver Cancer group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Spain

      2010

      Centro de Investigaci?n Biom?dica en Red de Enfermedades Hep?ticas y Digestivas (CIBERehd), Barcelona, Spain

      Unidad de Oncología Hepática (BCLC), Servicio de Hepatología, ICMDM, Hospital Clínic, IDIBAPS, Universidad de Barcelona, Barcelona, España

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Alejandro Forner is among the top experts in the world.
      Concept World rank
      radiography sorafenib #1
      ¿es útil #1
      hospital admissions cirrhosis #1
      conclusive diagnosis hcc #1
      enhancement pattern techniques #1
      cirrhosis liver unit #1
      radiography sorafenib spain #1
      spain raf kinases #1
      trials design interpretation #1
      complexity cholangiocarcinoma #1
      prognosis tumour burden #1
      alpha‐fetoprotein publication carcinoma #1
      hepatocellular carcinoma addendum #1
      advanced stage options #1
      association algorithms carcinoma #1
      liver ultrasonographic examination #1
      topic carcinoma germany #1
      liver mass widespread #1
      hospital admissions hcvcirrhosis #1
      recipients lower survival #1
      patients single icc #1
      single ≤ 2 #1
      complete radiologic necrosis #1
      distal dcca cca #1
      811 hiv counterparts #1
      techniques lesion biopsy #1
      covid‐19 liver disease #1
      tumoral nodules #1
      intermediate stage benefit #1
      hepatocellular decision trees #1
      linking prognosis #1
      seventyfour hivinfected patients #1
      carcinoma diagnóstico #1
      reliable strategy criteria #1
      admissions 2025 #1
      alphafetoproteins publication carcinoma #1
      study design endpoints #1
      chance liver cancer #1
      embolization increase survival #1
      histopathological features ihcc #1
      advancements years #1
      death alpha‐fetoprotein #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Alejandro Forner

      KOL-Index: 23491

      BACKGROUND: Patients undergoing liver transplantation for hepatocellular carcinoma within the Milan criteria (single tumour

      Known for Milan Criteria | Hepatocellular Carcinoma | Liver Transplantation | Microvascular Invasion | 5year Survival
      KOL-Index: 17301

      PURPOSE: To evaluate the diagnostic accuracy of the Liver Imaging Reporting and Data System (LI-RADS) with magnetic resonance (MR) imaging for hepatic nodules 20 mm or smaller detected during ultrasonographic (US) surveillance in patients with cirrhosis.

      MATERIALS AND METHODS: Between November 2003 and January 2010, patients with cirrhosis with a newly US-detected solitary hepatic nodule 20 mm or smaller were included in this institutional ethics committee-approved study. All patients ...

      Known for 20 Mm | Liver Imaging Reporting | Lirads Category | Magnetic Resonance Imaging | Patients Nodules
      KOL-Index: 14771

      BACKGROUND AND AIMS: Conventional pathological analysis fails to achieve sufficient sensitivity and specificity for the diagnosis of hepatocellular carcinoma (HCC) in small nodules. Immunohistochemical staining for glypican 3 (GPC3), heat shock protein 70 (HSP70) and glutamine synthetase (GS) has been suggested to allow a confident diagnosis but no prospective study has established the diagnostic accuracy of this approach. The aim of this study is to assess prospectively the diagnostic ...

      Known for Glutamine Synthetase | Immunohistochemical Panel | Hepatocellular Carcinoma | Diagnosis Hcc | Heat Shock
      KOL-Index: 14362

      This study assesses the magnetic resonance (MR) features of intrahepatic cholangiocarcinoma (ICC) in patients with cirrhosis with specific analysis of the contrast enhancement pattern. Cholangiocarcinoma may show increased contrast uptake in the arterial phase, and, if washout in the delayed venous phase were to be detected, the noninvasive diagnostic criteria proposed in the American Association for the Study of Liver Diseases guidelines would be refuted. We reviewed the MR findings of ...

      Known for Magnetic Resonance | Hepatocellular Carcinoma | Contrast Washout | Delayed Phases | Icc Cirrhosis
      KOL-Index: 13871

      BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma.

      METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not ...

      Known for Hepatocellular Carcinoma | Sorafenib Placebo | Patients Median Survival | Radiologic Progression | Preliminary Study
      KOL-Index: 13829

      This study prospectively evaluates the accuracy of contrast-enhanced ultrasound (CEUS) and dynamic magnetic resonance imaging (MRI) for the diagnosis of nodules 20 mm or smaller detected during ultrasound (US) surveillance. We included 89 patients with cirrhosis [median age, 65 years; male 53, hepatitis C virus 68, Child-Pugh A 80] without prior hepatocellular carcinoma (HCC) in whom US detected a small solitary nodule (mean diameter, 14 mm). Hepatic MRI, CEUS, and fine-needle biopsy ...

      Known for 20 Mm | Hepatic Nodules | Hepatocellular Carcinoma | Ceus Mri | Diagnosis Hcc
      KOL-Index: 11381

      BACKGROUND & AIMS: Transarterial chemoembolisation (TACE) improves survival of properly selected patients with hepatocellular carcinoma (HCC). Drug eluting beads (DEB) provide a calibrated and homogenous procedure while increasing efficacy. Outcome data applying this technology is lacking, and this is instrumental for clinical decision-making and for trial design. We evaluated the survival of HCC patients treated with DEB-TACE following a strict selection (preserved liver function, ...

      Known for Hepatocellular Carcinoma | Drug Eluting Beads | Patients Debtace | Tace Survival | Transarterial Chemoembolisation
      KOL-Index: 10919

      Sorafenib improves overall survival (OS) of patients with hepatocellular carcinoma (HCC) in the absence of objective response. Thus, time to tumor progression (TTP) is used to capture benefits of novel molecular agents, but proof of its surrogacy with survival is lacking. Furthermore, survival predictors upon progression are not established and there is a need to characterize postprogression survival (PPS) and assess with time-dependent covariates analysis if it is influenced by ...

      Known for Postprogression Survival | Trial Design | Hepatocellular Carcinoma | Progression Pattern | Pps Patients
      KOL-Index: 10199

      BACKGROUND & AIMS: To prospectively assess the diagnostic accuracy of the incorporation of additional magnetic resonance imaging (MRI) parameters in those based on contrast enhancement pattern for the diagnosis of solitary nodules between 5 and 20mm, detected during surveillance in patients with cirrhosis.

      METHODS: Between November 2003 and January 2010, we prospectively included 159 cirrhotic patients with a newly detected solitary nodule between 5 and 20mm in diameter by screening ...

      Known for Hepatocellular Carcinoma | Hcc Cirrhosis | Sensitivity Specificity | Enhancement Pattern | Benign Lesions
      KOL-Index: 9704

      Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, intermediate-stage HCC includes a heterogeneous population of patients with varying tumour burdens, liver function (Child-Pugh A or B) and disease aetiology. This suggests that not all patients with intermediate-stage HCC will derive similar benefit from TACE, and that some patients may benefit from other treatment options. Results of an ...

      Known for Tace Patients | Stage Hepatocellular | Treatment Hcc | Transarterial Chemoembolization | Liver Function
      KOL-Index: 9683

      BACKGROUND: Evaluation of response to treatment is a key aspect in cancer therapy. Response Evaluation Criteria in Solid Tumors (RECIST) are used in most oncology trials, but those criteria evaluate only unidimensional tumor measurements and disregard the extent of necrosis, which is the target of all effective locoregional therapies. Therefore, the European Association for the Study of the Liver (EASL) guidelines recommended that assessment of tumor response should incorporate the ...

      Known for Tumor Response | Locoregional Therapies | Easl Guidelines | Hepatocellular Carcinoma | European Association
      KOL-Index: 9651

      The aim of this study was to describe the imaging features by contrast-enhanced ultrasound (CEUS) of intrahepatic cholangiocarcinoma (ICC) in cirrhosis patients. We registered the CEUS images of cirrhosis patients with histologically confirmed ICC. In all cases magnetic resonance imaging (MRI) was done to confirm the diagnosis and/or staging purposes. A total of 21 patients met all the criteria to be included in the study. The median nodule size was 32 mm. All nodules showed contrast ...

      Known for Cirrhosis Patients | Hepatocellular Carcinoma | Vascular Pattern | Icc Cases | Intrahepatic Peripheral
      KOL-Index: 9258

      BACKGROUND/AIMS: This study assesses the safety, pharmacokinetics and efficacy of transarterial chemoembolization using drug eluting beads (DEB), an embolizing device that slowly releases chemotherapy to decrease systemic toxicity.

      METHODS: Twenty-seven Child-Pugh A cirrhotics (76% male, 59% HCV) with untreated large/multifocal HCC received chemoembolization with doxorubicin loaded DEBs at doses adjusted for bilirubin and body surface (range: 47-150 mg). Clinical and analytical data were ...

      Known for Drug Eluting Beads | Doxorubicin Pharmacokinetics | Hepatocellular Carcinoma | 6 Months | Systemic Toxicity
      KOL-Index: 9256

      A decade ago we proposed to enlist for transplantation those patients with resected hepatocellular carcinoma in whom pathology registered pejorative histological markers (microvascular invasion and/or satellites; ab initio indication) and not wait for the appearance of recurrence. This study evaluates the outcome of this approach. From 1995 to 2012, 164 patients with hepatocellular carcinoma underwent resection. Eighty-five patients were potential candidates for liver transplantation and ...

      Known for Liver Transplantation | Patients Recurrence | Hepatocellular Carcinoma | 5year Survival | Aged Neoplasm
      KOL-Index: 8746

      BACKGROUND: The sole effective option for patients with advanced HCC is sorafenib and there is an urgent need to develop new therapeutic approaches. Immunotherapy is a promising option that deserves major investigation. In this open label, single arm clinical trial, we analyzed the effect of a low dose cyclophosphamide treatment in combination with a telomerase peptide (GV1001) vaccination in patients with advanced HCC.

      METHODS: 40 patients with advanced HCC were treated with 300 mg/m2 ...

      Known for Advanced Hcc | Peptide Vaccination | Liver Neoplasms | Vaccines Carcinoma | Hepatocellular Chemotherapy

      Key People For Hepatocellular Carcinoma

      Top KOLs in the world
      #1
      Jordi Bruix
      hepatocellular carcinoma liver transplantation patients hcc
      #2
      Josep María Llovet
      hepatocellular carcinoma advisory consultancy liver transplantation
      #3
      Vincenzo Mazzaferro
      hepatocellular carcinoma liver transplantation patients hcc
      #4
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #5
      Jacques Ferlay
      cancer incidence global burden latin america
      #6
      Hashem B EL‐SERAG
      united states hepatocellular carcinoma veterans affairs

      Liver Unit, Barcelona Clinic Liver Cancer (BCLC) Group, Hospital Clinic Barcelona. IDIBAPS, University of Barcelona, Barcelona, Spain | BCLC group, Liver Unit, Hospital Clínic Barcelona. IDIBAPS, University of Barcelona, Barcelona, Spain | Barcelona

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.